共 4 条
[1]
[2]
[3]
[4]
Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies.[J].Takahisa Furuta;Naohito Shirai;Mitsushige Sugimoto;Akiko Nakamura;Akira Hishida;Takashi Ishizaki.Drug Metabolism and Pharmacokinetics.2005, 3

